IAM Stock Forecast: Iambic Therapeutics, Inc. Price Predictions for 2026-2027
The 4 Wall Street analysts covering Iambic Therapeutics, Inc. hold a median 12-month price target of $26 — +98.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 1 of 100 as at 21 Nov 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Iambic Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (33): Analysts have, on balance, been raising their forecasts.
Momentum (1): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
IAM stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on IAM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +98.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Nov 2026 | Jefferies | Initiates | Buy | $35 |
| 9 Nov 2026 | B of A Securities | Initiates | Buy | $30 |
| 9 Nov 2026 | Citigroup | Initiates | Buy | $22 |
| 9 Nov 2026 | JP Morgan | Initiates | Overweight | $22 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for IAM.
This page is one stock. Monday covers all of them.
IAM appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
IAM vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
IAM analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 34.0×
- Price / book
- —
- EV / EBITDA
- —
Cheaper than 6% of US stocks
- Revenue growth (YoY)
- 224.7%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 96% of US stocks
- Return on equity
- —
- Return on assets
- —
- Dividend yield
- —
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Iambic Therapeutics, Inc. has a market value of $621.4M and an enterprise value of $528.0M.
Iambic Therapeutics, Inc. employs 171 people.
Data provided by Twelve Data
IAM and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at IAM’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Iambic Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about IAM
What is the IAM stock price forecast for 2026-2027?
The 4 Wall Street analysts covering Iambic Therapeutics, Inc. have a median 12-month price target of $26, with estimates ranging from $22 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is IAM stock a buy right now?
Of the 4 analysts covering Iambic Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Iambic Therapeutics, Inc. 1 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank IAM?
As at 21 Nov 2026, Iambic Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (33 of 100).
Will IAM stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts implies +98.3% from the last close, and Ticker Nerd's factor model ranks Iambic Therapeutics, Inc. 1 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the IAM stock forecast for 2030?
No analyst covering Iambic Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IAM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $35 over the next 12 months.
What does Iambic Therapeutics, Inc. do?
Iambic Therapeutics, Inc. is a clinical-stage biotechnology and life sciences company developing small-molecule medicines through an AI-driven drug discovery platform. Its molecular superintelligence approach combines proprietary artificial intelligence with automated, scalable chemistry and biology experiments to identify drug candidates, refine their characteristics, and support development across therapeutic areas.
About Iambic Therapeutics, Inc.
Iambic Therapeutics, Inc. is a clinical-stage biotechnology and life sciences company developing small-molecule medicines through an AI-driven drug discovery platform. Its molecular superintelligence approach combines proprietary artificial intelligence with automated, scalable chemistry and biology experiments to identify drug candidates, refine their characteristics, and support development across therapeutic areas. The company’s current pipeline includes IAM1363, a selective HER2 inhibitor being evaluated in an early-stage clinical trial for patients with HER2-altered solid tumors, as well as preclinical programs targeting KIF18A and CDK2/4. Iambic also provides technology capabilities centered on molecular design, predictive modeling, and experimental validation, including its Enchant and NeuralPLexer systems. Based in San Diego, California, Iambic operates at the intersection of biotechnology, computational science, and pharmaceutical research. Its business model and platform position it within the growing AI-enabled drug discovery market, where advanced computation and laboratory automation are used to improve the identification and optimization of potential therapeutics.
CEO Dr. Thomas Miller Ph.D. · 171 employees · United States · https://www.iambic.ai